Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | DKK1 | O94907 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034085 | 0.81 | NR4A2 (0.54) | MEN1KMT2AHTTCYP1A2GSK3B | |
| SCHEMBL27029472 | 0.81 | NPC1 (0.62) | MEN1KMT2AHTTGSK3BSMN1; SMN2 | |
| SCHEMBL30892080 | 0.81 | CYP1A2 (0.63) | MEN1KMT2ACYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL12211131 | 0.81 | CYP1A2 (0.63) | MEN1KMT2ACYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL10042675 | 0.81 | MEN1 (0.48) | MEN1KMT2AGSK3BSMN1; SMN2ALDH1A1 | |
| SCHEMBL13934821 | 0.80 | NPC1 (0.55) | MEN1KMT2AHTTCYP1A2NPC1 | |
| SCHEMBL16161191 | 0.79 | KMT2A (0.55) | MEN1KMT2AHTTCYP1A2SMN1; SMN2 | |
| SCHEMBL10051516 | 0.79 | MEN1 (0.67) | MEN1KMT2ACYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL445042 | 0.79 | MEN1 (0.59) | MEN1KMT2ASMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL25178278 | 0.79 | MEN1 (0.50) | MEN1KMT2AGSK3BSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230403927-A1 | AROMATIC COMPOUNDS | UDC IRELAND LTD (IE) | 2023-12-14 | — | — | US | disclosed |
| US-20230403927-A1 | AROMATIC COMPOUNDS | UDC IRELAND LTD (IE) | 2023-12-14 | — | — | US | disclosed |
| US-11800787-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2023-10-24 | — | — | US | disclosed |
| US-11800787-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2023-10-24 | — | — | US | disclosed |
| EP-3160976-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-20170141329-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | disclosed |
| US-20170141329-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | disclosed |
| US-8846903-B2 | Acyl-urea derivatives and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-09-30 | — | — | US | disclosed |
| EP-2613775-B1 | N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | disclosed |
| US-8716285-B2 | N-hydroxy-benzamids for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2009026326-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026326-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026319-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026319-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009001356-A2 | ACYL-UREA DERIVATIVES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-12-31 | — | — | WO | disclosed |
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2008-11-20 | — | — | US | disclosed |
| US-20030055263-A1 | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-20 | — | — | US | disclosed |
| WO-2003006443-A2 | 2- 4-(NAPHTALIN-2-YL)-THIAZOL-2-YLAMINOCARBONYL BENZOIC ACID AND 2- 4-(NAPHTALIN-2-YL)-PYRIMIDIN-2-YLAMINOCARBONYL BENZOIC ACID AND ADDITIONAL COMPOUNDS SERVING AS TELOMERASE INHIBITORS FOR USE IN TUMOR THERAPY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230403927-A1 | AROMATIC COMPOUNDS | TYR, CTCF, MITF | MEN1 2141/4885KMT2A 1055/4885HTT 753/4885 |
| US-20080287452-A1 | HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT3A, CTNNB1, WNT1 | MEN1 3636/4885KMT2A 3865/4885HTT 1218/4885 |
| US-20170141329-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | MEN1 766/4885KMT2A 2648/4885HTT 2249/4885 |
| US-20030055263-A1 | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production | TERT, POT1, REV1 | MEN1 386/4885KMT2A 2592/4885HTT 1497/4885 |
| US-11800787-B2 | Metal complexes | AP1M1, SOD1, AP3M1 | MEN1 766/4885KMT2A 2648/4885HTT 2249/4885 |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | MEN1 3503/4885KMT2A 4198/4885HTT 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.